Lasa Supergenerics Limited has informed the Exchange regarding a press release dated April 24, 2025, titled "Press Release titled Lasa Supergenerics Limited Announces the Expansion of Manufacturing Capacity of API Albendazole to meet the Growing Demands issued by the Company. ".
LASA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lasa Supergenerics Limited has expanded the manufacturing capacity of its key product, Albendazole USP (an Active Pharmaceutical Ingredient), at its facility in Maharashtra. The expansion was done by debottlenecking existing infrastructure and adding new machinery, which is expected to increase total capacity by around 20%. The company has invested about Rs. 100 lakhs in capex for this expansion, with some already spent and more to be deployed over time. The move aims to meet growing demand in both Indian and international markets, improve product efficiency, and reduce delivery lead times. The company is a leading manufacturer of veterinary APIs and also serves the human healthcare segment.
This is a positive development for shareholders, as capacity expansion of 20% positions the company to capture rising global demand for Albendazole and grow revenues. The modest capex of Rs. 100 lakhs suggests limited balance sheet stress, though the actual revenue and margin impact will depend on how quickly new capacity gets utilised.